Blood oxytocin levels and the rs4686302 polymorphism of the oxytocin receptor gene in patients with adenomyosis

In: Journal of obstetrics and women's diseases · 2023 · vol. 72(6) , pp. 97–104 · doi:10.17816/jowd487470 · W4391725756
article OA: closed CC0
Full text JSON View on OpenAlex View at publisher
AI-generated summary by claude@2026-06, 2026-06-08

This study found higher blood oxytocin levels and a more frequent minor allele of the OXTR rs4686302 polymorphism in adenomyosis patients compared to controls.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

AI-generated deep summary by claude@2026-06, 2026-06-08 · read from full text

This original study measured blood oxytocin levels and assessed the oxytocin receptor gene polymorphism rs4686302 in reproductive-age women, comparing 56 patients with adenomyosis to 33 healthy controls for oxytocin (ELISA) and 79 adenomyosis patients to 49 controls for genotype analysis (PCR-RFLP). The authors found significantly higher blood oxytocin levels in adenomyosis patients versus controls, and the rs4686302 minor A allele was more frequent in adenomyosis (28.5%) than in controls (13.3%), with A-allele carriers having higher odds of adenomyosis (OR 2.44, 95% CI 1.13–5.28). The paper’s limitation is that it describes associations between oxytocin, OXTR genotype, and adenomyosis but does not establish causality or provide functional confirmation of how rs4686302 alters adenomyosis biology beyond prior background evidence. This paper is centrally about adenomyosis — it evaluates blood oxytocin levels and OXTR rs4686302 polymorphism as potential contributors to adenomyosis pathogenesis.

Read from the paper's body, not the abstract. Not a substitute for reading the paper. No clinical advice. How this works

Abstract

BACKGROUND: An in-depth study of the pathogenesis of adenomyosis and the development of new therapeutic approaches are extremely relevant. Atosiban, a competitive oxytocin receptor antagonist, may be a promising drug with a potential therapeutic effect. Oxytocin is involved in the pathogenesis of adenomyosis-associated dysmenorrhea, and there is evidence of increased expression of the oxytocin receptor (OXTR) in the myometrium in adenomyosis and the association of the OXTR gene polymorphic variant rs4686302 with oxytocin-induced myometrial contractility. AIM: The aim of this study was to evaluate blood oxytocin levels and the frequency of the polymorphic variants of the oxytocin receptor gene (OXTR) rs4686302 polymorphism in patients with adenomyosis and in healthy women of reproductive age. MATERIALS AND METHODS: The levels of oxytocin in the blood plasma were measured by competitive enzyme immunoassay (ELISA) in patients with adenomyosis (n = 56, with mean age of 37.5 ± 8.54 years), and in women without gynecological diseases (control group; n = 33, with mean age of 32.1 ± 5.40 years). The polymorphic variant rs4686302 of the OXTR gene was analyzed by PCR-RFLP analysis in patients with adenomyosis (n = 79, with mean age of 39.9 ± 7.74 years) and in control group patients (n = 49, with mean age of 37.0 ± 9.20 years). The chi-square (χ2) test was used to analyze the distribution of genotypes and alleles. Statistical data processing was performed using the Jamovi Software, Version 1.2.27 for Windows. RESULTS: In patients with adenomyosis, the level of oxytocin in the blood serum was significantly higher than in control group patients: 130.0 ± 27.9 pg/ml and 95.9 ± 26.7 pg/ml, respectively. The minor allele A of the OXTR gene polymorphic variant rs4686302 was significantly more common in patients with adenomyosis (28.5%) than in women in the control group (13.3%) and in the general sample (11–15% according to the 1000 Genomes Project). The odds of developing adenomyosis in patients with the presence of the A allele (the G/A and A/A genotypes) were 2.44 times higher compared to patients with the G/G genotype (OR 2.44, 95% CI 1.13–5.28). CONCLUSIONS: The data obtained suggest the participation of oxytocin and its receptor in the pathogenesis of adenomyosis and requires further research in this direction.
Full text 9,911 characters · extracted from oa-doi-fallback · 5 sections · click to expand

Abstract

BACKGROUND: An in-depth study of the pathogenesis of adenomyosis and the development of new therapeutic approaches are extremely relevant. Atosiban, a competitive oxytocin receptor antagonist, may be a promising drug with a potential therapeutic effect. Oxytocin is involved in the pathogenesis of adenomyosis-associated dysmenorrhea, and there is evidence of increased expression of the oxytocin receptor (OXTR) in the myometrium in adenomyosis and the association of the OXTR gene polymorphic variant rs4686302 with oxytocin-induced myometrial contractility. AIM: The aim of this study was to evaluate blood oxytocin levels and the frequency of the polymorphic variants of the oxytocin receptor gene (OXTR) rs4686302 polymorphism in patients with adenomyosis and in healthy women of reproductive age.

Materials and methods

The levels of oxytocin in the blood plasma were measured by competitive enzyme immunoassay (ELISA) in patients with adenomyosis (n = 56, with mean age of 37.5 ± 8.54 years), and in women without gynecological diseases (control group; n = 33, with mean age of 32.1 ± 5.40 years). The polymorphic variant rs4686302 of the OXTR gene was analyzed by PCR-RFLP analysis in patients with adenomyosis (n = 79, with mean age of 39.9 ± 7.74 years) and in control group patients (n = 49, with mean age of 37.0 ± 9.20 years). The chi-square (χ2) test was used to analyze the distribution of genotypes and alleles. Statistical data processing was performed using the Jamovi Software, Version 1.2.27 for Windows.

Results

In patients with adenomyosis, the level of oxytocin in the blood serum was significantly higher than in control group patients: 130.0 ± 27.9 pg/ml and 95.9 ± 26.7 pg/ml, respectively. The minor allele A of the OXTR gene polymorphic variant rs4686302 was significantly more common in patients with adenomyosis (28.5%) than in women in the control group (13.3%) and in the general sample (11–15% according to the 1000 Genomes Project). The odds of developing adenomyosis in patients with the presence of the A allele (the G/A and A/A genotypes) were 2.44 times higher compared to patients with the G/G genotype (OR 2.44, 95% CI 1.13–5.28).

Conclusions

The data obtained suggest the participation of oxytocin and its receptor in the pathogenesis of adenomyosis and requires further research in this direction. Full Text About the authors Elena A. Netreba The Research Institute of Obstetrics, Gynecology and Reproductology named after D.O. Ott Email: [email protected] ORCID iD: 0000-0002-0485-3612 SPIN-code: 9193-3154 Russian Federation, Saint Petersburg Maria I. Yarmolinskaya The Research Institute of Obstetrics, Gynecology and Reproductology named after D.O. Ott Email: [email protected] ORCID iD: 0000-0002-6551-4147 SPIN-code: 3686-3605 MD, Dr. Sci. (Med.), Professor of the Russian Academy of Sciences Russian Federation, Saint PetersburgOlga V. Malysheva The Research Institute of Obstetrics, Gynecology and Reproductology named after D.O. Ott Email: [email protected] ORCID iD: 0000-0002-8626-5071 SPIN-code: 1740-2691 Cand. Sci. (Biol.) Russian Federation, Saint PetersburgMaria A. Shalina The Research Institute of Obstetrics, Gynecology and Reproductology named after D.O. Ott Email: [email protected] ORCID iD: 0000-0002-5921-3217 SPIN-code: 6673-2660 MD, Cand. Sci. (Med.) Russian Federation, Saint PetersburgNatalia N. Tkachenko The Research Institute of Obstetrics, Gynecology and Reproductology named after D.O. Ott Email: [email protected] ORCID iD: 0000-0001-6189-3488 SPIN-code: 9633-6701 Cand. Sci. (Biol.) Russian Federation, Saint PetersburgAnastasia V. Koloshkina The Research Institute of Obstetrics, Gynecology and Reproductology named after D.O. Ott Email: [email protected] ORCID iD: 0000-0002-5200-7672 Russian Federation, Saint Petersburg

References

- Benagiano G, Brosens I. History of adenomyosis. Best Pract Res Clin Obstet Gynaecol. 2006;20(4):449–463. doi: 10.1016/j.bpobgyn.2006.01.007 - Naftalin J, Hoo W, Pateman K, et al. How common is adenomyosis? A prospective study of prevalence using transvaginal ultrasound in a gynaecology clinic. Hum Reprod. 2012;27(12):3432–3439. doi: 10.1093/humrep/des332 - Maheshwari A, Gurunath S, Fatima F, et al. Adenomyosis and subfertility: a systematic review of prevalence, diagnosis, treatment and fertility outcomes. Hum Reprod Update. 2012;18(4):374–392. doi: 10.1093/humupd/dms006 - Younes G, Tulandi T. Effects of adenomyosis on in vitro fertilization treatment outcomes: a meta-analysis. Fertil Steril. 2017;108(3):483–490.e3. doi: 10.1016/j.fertnstert.2017.06.025 - Juang CM, Chou P, Yen MS, et al. Adenomyosis and risk of preterm delivery. BJOG. 2007;114(2):165–169. doi: 10.1111/j.1471-0528.2006.01186.x - Hashimoto A, Iriyama T, Sayama S, et al. Adenomyosis and adverse perinatal outcomes: increased risk of second trimester miscarriage, preeclampsia, and placental malposition. J Matern Fetal Neonatal Med. 2018;31(3):364–369. doi: 10.1080/14767058.2017.1285895 - Scala C, Leone Roberti Maggiore U, Racca A, et al. Influence of adenomyosis on pregnancy and perinatal outcomes in women with endometriosis. Ultrasound Obstet Gynecol. 2018;52(5):666–671. doi: 10.1002/uog.18989 - Bertucci E, Sileo FG, Diamanti M, et al. How adenomyosis changes throughout pregnancy: a retrospective cohort study. Int J Gynaecol Obstet. 2023;160(3):856–863. doi: 10.1002/ijgo.14383 - Gordts S, Grimbizis G, Campo R. Symptoms and classification of uterine adenomyosis, including the place of hysteroscopy in diagnosis. Fertil Steril. 2018;109(3):380–388.e1. doi: 10.1016/j.fertnstert.2018.01.006 - Gao X, Outley J, Botteman M, et al. Economic burden of endometriosis. Fertil Steril. 2006;86(6):1561–1572. doi: 10.1016/j.fertnstert.2006.06.015 - Yarmolinskaya MI, Shalina MA, Khachaturyan AR, et al. Adenomyosis: from scientific discoveries to the practical aspects of prescribing drug therapy. Obstetrics and Gynecology. 2020;(3):182–190. (In Russ.) doi: 10.18565/aig.2020.3.182-190 - Guo SW, Mao X, Ma Q, et al. Dysmenorrhea and its severity are associated with increased uterine contractility and overexpression of oxytocin receptor (OTR) in women with symptomatic adenomyosis. Fertil Steril. 2013;99(1):231–240. doi: 10.1016/j.fertnstert.2012.08.038 - Orazov MR, Radzinsky VE, Lokshin V N, et al. The role of oxytocin and vasopressin receptors in the pathogenesis of pelvic pain caused by adenomyosis. Patologicheskaya fiziologiya i eksperimental’naya terapiya. 2019;63(2):99–107. (In Russ.) doi: 10.25557/0031-2991.2019.02.99-107 - Akerlund M. The role of oxytocin and vasopressin in the initiation of preterm and term labour as well as primary dysmenorrhoea. Regul Pept. 1993;45(1–2):187–191. doi: 10.1016/0167-0115(93)90204-l - Akerlund M, Melin P, Maggi M. Potential use of oxytocin and vasopressin V1a antagonists in the treatment of preterm labour and primary dysmenorrhoea. Adv Exp Med Biol. 1995;395:595–600. - Steinwall M, Bossmar T, Gaud C, et al. Inhibitory effects of SR 49059 on oxytocin-and vasopressin-induced uterine contractions in non-pregnant women. Acta Obstet Gynecol Scand. 2004;83(1):12–18. doi: 10.1111/j.1600-0412.2004.00320.x - Akerlund M. Involvement of oxytocin and vasopressin in the pathophysiology of preterm labor and primary dysmenorrhea. Prog Brain Res. 2002;139:359–365. doi: 10.1016/s0079-6123(02)39030-7 - Richter ON, Tschubel K, Schmolling J, et al. Immunohistochemical reactivity of myometrial oxytocin receptor in extracorporeally perfused nonpregnant human uteri. Arch Gynecol Obstet. 2003;269(1):16–24. doi: 10.1007/s00404-003-0474-0 - Richter ON, Bartz C, Dowaji J, et al. Contractile reactivity of human myometrium in isolated non-pregnant uteri. Hum Reprod. 2006;21(1):36–45. doi: 10.1093/humrep/dei295 - Lesny P, Killick SR. The junctional zone of the uterus and its contractions. BJOG. 2004;111(11):1182–1189. doi: 10.1111/j.1471-0528.2004.00350.x - Mechsner S, Grum B, Gericke C, et al. Possible roles of oxytocin receptor and vasopressin-1α receptor in the pathomechanism of dysperistalsis and dysmenorrhea in patients with adenomyosis uteri. Fertil Steril. 2010;94(7):2541–2546. doi: 10.1016/j.fertnstert.2010.03.015 - Nie J, Liu X, Guo SW. Immunoreactivity of oxytocin receptor and transient receptor potential vanilloid type 1 and its correlation with dysmenorrhea in adenomyosis. Am J Obstet Gynecol. 2010;202(4):346.e1–346.e3468. doi: 10.1016/j.ajog.2009.11.035 - Zhang Y, Yu P, Sun F, et al. Expression of oxytocin receptors in the uterine junctional zone in women with adenomyosis. Acta Obstet Gynecol Scand. 2015;94(4):412–418. doi: 10.1111/aogs.12595 - Kim J, Stirling KJ, Cooper ME, et al. Sequence variants in oxytocin pathway genes and preterm birth: a candidate gene association study. BMC Med Genet. 2013;14:77. doi: 10.1186/1471-2350-14-77 - Füeg F, Santos S, Haslinger C, et al. Influence of oxytocin receptor single nucleotide sequence variants on contractility of human myometrium: an in vitro functional study. BMC Med Genet. 2019;20(1):178. doi: 10.1186/s12881-019-0894-8 - He Y, Wu H, He X, et al. Administration of atosiban in patients with endometriosis undergoing frozen-thawed embryo transfer: a prospective, randomized study. Fertil Steril. 2016;106(2):416–422. doi: 10.1016/j.fertnstert.2016.04.019

Text is read by the "Ask this paper" AI Q&A widget below. Extraction quality varies by source — PMC NXML preserves structure cleanly, OA-HTML may include some navigation residue, and OA-PDF can have broken hyphenation. The publisher copy (via DOI) is the canonical version.

My notes (saved in your browser only)

Ask this paper AI returns verbatim quotes from the full text · source: oa-doi-fallback

Answers must be backed by verbatim quotes from this paper's full text. Hallucinated quotes are dropped automatically; if no verbatim passage answers the question, we say so. How this works

Condition tags

adenomyosisdysmenorrhea

Citation neighborhood

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.

References (25)

Source provenance

openalex
last seen: 2026-06-04T00:00:01.174412+00:00
License: CC0 · commercial use OK